


10/551,816

STM-structure search
1/11/07

=> d ibib abs hitstr

ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STM
ACCESSION NUMBER: 2004:927208 CAPLUS
DOCUMENT NUMBER: 141:395550
TITLE: Processes for producing carboxyphenylindazole derivatives as intermediates for pyrazoloacridone derivatives
INVENTOR(S): Tsubakihara, Nobuaki; Katsuhira, Takeshi; Kinugawa, Masahiko; Kato, Nobuyuki
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094423	A1	20041104	WO 2004-JP5891	20040423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004232605	A1	20041104	AU 2004-232605	20040423
EP 1627877	A1	20060222	EP 2004-729194	20040423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2006217554	A1	20060928	US 2005-551816	20050930
PRIORITY APPLN. INFO.:			JP 2003-119943	A 20030424
			WO 2004-JP5891	W 20040423
OTHER SOURCE(S):		MARPAT 141:395550		
GI				




AB Carboxyphenylindazole derivs. I [R = alkyl; R1 = H, CH2X, etc.; R2 = H, nitro, etc.; X = H, OH, etc.], useful as intermediates for antitumor pyrazoloacridone derivs., are prepared, e.g. by reaction of indazole derivs. with fluoroalkoxybenzonitrile derivs., followed by hydrolysis of the resulting cyanophenylindazole derivs. Thus, reaction of 2-fluoro-6-methoxybenzonitrile with 3-methyl-6-nitroindazole in the presence of potassium carbonate in DMF, followed by hydrolysis of the

10/551,816

product, gave 1-(2-carboxy-3-methoxyphenyl)-3-methyl-6-nitroindazole.
IT 786658-34-2P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for producing carboxyphenylindazole derivs. as intermediates for pyrazoloacridone derivs.)
RN 786658-34-2 CAPLUS
CN Benzonitrile, 2-methoxy-6-(3-methyl-6-nitro-1H-indazol-1-yl)- (9CI) (CA INDEX NAME)



IT 786658-39-7P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for producing carboxyphenylindazole derivs. as intermediates for pyrazoloacridone derivs.)
RN 786658-39-7 CAPLUS
CN Benzonitrile, 2-fluoro-6-(3-methyl-6-nitro-1H-indazol-1-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d re 1-5

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
RE

- (1) Kyowa Hakko Kogyo Co Ltd; JP 02-76878 A 1990 CAPLUS
- (2) Kyowa Hakko Kogyo Co Ltd; EP 347749 A1 1990 CAPLUS
- (3) Kyowa Hakko Kogyo Co Ltd; US 5079358 A 1990 CAPLUS
- (4) Kyowa Hakko Kogyo Co Ltd; JP 06-107641 A 1994 CAPLUS
- (5) Kyowa Hakko Kogyo Co Ltd; JP 07-48355 A 1995 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 10:20:25 ON 11 JAN 2007)

FILE 'REGISTRY' ENTERED AT 10:20:45 ON 11 JAN 2007

L1 STRUCTURE UPLOADED
L2 0 S L1

10/551,816

L3 2 S L1 FULL


FILE 'CAPLUS' ENTERED AT 10:21:21 ON 11 JAN 2007

L4 1 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 MeO, EtO, n-PrO, i-PrO, n-BuO, i-BuO, s-BuO, t-BuO, X

Structure attributes must be viewed using STN Express query preparation.

=> => d ibib abs hitstr

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:927208 CAPLUS

DOCUMENT NUMBER: 141:395550

TITLE: Processes for producing carboxyphenylindazole derivatives as intermediates for pyrazoloacridone derivatives

INVENTOR(S): Tsubakihara, Nobuaki; Katsuhira, Takeshi; Kinugawa, Masahiko; Kato, Nobuyuki

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094423	A1	20041104	WO 2004-JP5891	20040423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004232605	A1	20041104	AU 2004-232605	20040423
EP 1627877	A1	20060222	EP 2004-729194	20040423
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

10/551,816


IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
US 2006217554 A1 20060928 US 2005-551816 20050930
PRIORITY APPLN. INFO.: JP 2003-119943 A 20030424
WO 2004-JP5891 W 20040423
OTHER SOURCE(S): MARPAT 141:395550
GI



AB Carboxyphenylindazole derivs. I [R = alkyl; R1 = H, CH2X, etc.; R2 = H, nitro, etc.; X = H, OH, etc.], useful as intermediates for antitumor pyrazoloacridone derivs., are prepared, e.g. by reaction of indazole derivs. with fluoroalkoxybenzonitrile derivs., followed by hydrolysis of the resulting cyanophenylindazole derivs. Thus, reaction of 2-fluoro-6-methoxybenzonitrile with 3-methyl-6-nitroindazole in the presence of potassium carbonate in DMF, followed by hydrolysis of the product, gave 1-(2-carboxy-3-methoxyphenyl)-3-methyl-6-nitroindazole.

IT 786658-34-2P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for producing carboxyphenylindazole derivs. as intermediates for pyrazoloacridone derivs.)

RN 786658-34-2 CAPLUS
CN Benzonitrile, 2-methoxy-6-(3-methyl-6-nitro-1H-indazol-1-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:20:25 ON 11 JAN 2007)

FILE 'REGISTRY' ENTERED AT 10:20:45 ON 11 JAN 2007

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 2 S L1 FULL

10/551,816

FILE 'CAPLUS' ENTERED AT 10:21:21 ON 11 JAN 2007

L4 1 S L3

FILE 'REGISTRY' ENTERED AT 10:22:52 ON 11 JAN 2007

L5 STRUCTURE UPLOADED

L6 0 S L5

L7 1 S L5 FULL


FILE 'CAPLUS' ENTERED AT 10:23:58 ON 11 JAN 2007

L8 1 S L7

=> d 15

L5 HAS NO ANSWERS

L5 STR



G1 MeO, EtO, n-PrO, i-PrO, n-BuO, i-BuO, s-BuO, t-BuO, X

Structure attributes must be viewed using STN Express query preparation.

=>

10/551,816

=> d ibib abs hitstr 1-5


L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:149503 CAPLUS
DOCUMENT NUMBER: 139:254492
TITLE: KW-2170 (Kyowa Hakko Kogyo)
AUTHOR(S): Verschraegen, Claire F.
CORPORATE SOURCE: UNM Cancer Research and Treatment Center, Albuquerque,
NM, 87131, USA
SOURCE: IDrugs (2002), 5(10), 1000-1003
CODEN: IDRUFN; ISSN: 1369-7056
PUBLISHER: PharmaPress Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. The pyrazoloacridone KW-2170, an alkylating agent and topoisomerase II inhibitor, is being developed by Kyowa Hakko Kogyo as a potential treatment for cancer. By Dec. 2001, KW-2170 had entered phase II trials in the US, following approval for the trial from the FDA, which was received in Nov. 2001. At this time, the company planned to extend the phase II trials to Australia, Singapore, Taiwan and Costa Rica, using data from US phase I trials. Accelerated Japanese trials were also planned, and an NDA was anticipated for 2006, with non-small-cell lung cancer, prostate cancer, colorectal cancer, ovarian cancer and breast cancer as the targets. By August 2002, Japanese phase I trials had been completed.

IT 207862-44-0P, KW 2170
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(KW-2170 pharmacol. as antitumor agent)

RN 207862-44-0 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[[(2-hydroxyethyl)amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:376708 CAPLUS
DOCUMENT NUMBER: 131:170298
TITLE: An efficient synthesis of a new class of DNA intercalating antitumor 7,10-dihydroxy-6H-pyrazolo[4,5,1-de]acridin-6-ones
AUTHOR(S): Mimura, Takashi; Kato, Nobuyuki; Sugaya, Toru; Ikuta,


CORPORATE SOURCE: Masanori; Kato, Sachiko; Kuge, Yukihiro; Tomioka, Shinji; Kasai, Masaji
 Sakai Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Sakai, 590, Japan
 SOURCE: Synthesis (1999), (6), 947-952
 CODEN: SYNTBF; ISSN: 0039-7881
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:170298

AB An efficient synthesis of KW-2170, a 7,10-dihydroxy-6H-pyrazolo[4.5.1-de]acridin-6-one, is described. The selective monobromination of the Me group before the cyclization to the pyrazoloacridone is easily carried out. In the improved process, the bromination of the corresponding Me group is achieved prior to the hydroquinone formation, so the protection of the hydroxy groups is not necessary unlike the original method. In comparison with the original synthetic route of KW-2170, the new route decreases the synthetic steps from 2,6-Br(MeO)C₆H₃CO₂H from 15 to 13 and increases the overall yield from 2 to 12%.

IT 238756-65-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of KW-2170, hydroxypyrazoloacridinone)

RN 238756-65-5 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-8-bromo-7,10-dihydroxy-2-[[2-hydroxyethyl(phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




IT 207862-44-0P, KW-2170

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of KW-2170, hydroxypyrazoloacridinone)

RN 207862-44-0 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[2-hydroxyethyl(phenylmethyl)amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)





● 2 HCl

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4. ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:909448 CAPLUS
 DOCUMENT NUMBER: 123:313951
 TITLE: Preparation of pyrazoloacridones as antitumor agents
 INVENTOR(S): Kato, Nobuyuki; Mimura, Takashi; Ikuta, Masanori; Iida, Sachiko; Sugaya, Tooru; Kasai, Masaji; Tomioka, Shinji
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Kk, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07165758	A	19950627	JP 1993-315123	19931215
JP 3283369	B2	20020520		
PRIORITY APPLN. INFO.:			JP 1993-315123	19931215
OTHER SOURCE(S):			CASREACT 123:313951; MARPAT 123:313951	
GI				




AB Claimed is the process for the preparation of pyrazoloacridones I [X = H, halo; W, Y = H, halo, etc.] by reduction of pyrazoloacridinetrienes II [X, W, Y = as defined above]. I are antitumor agents (no data). Thus, reduction of II [X = Y = Br; W = H] by sodium hydrosulfite gave I [X = Y = Br; W = H].
 IT 142853-45-OP 170105-05-2P
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP. (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazoloacridones as antitumor agents)

10/551,816


RN 142853-45-0 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[2-(2-hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 170105-05-2 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 8-bromo-7,10-dihydroxy-2-[[2-(2-hydroxyethyl)(phenylmethyl)amino]methyl]-5-[(phenylmethyl)[3-[(phenylmethyl)amino]propyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:867580 CAPLUS

DOCUMENT NUMBER: 123:256702

TITLE: Preparation of acridone and pyrazoloacridinone derivatives as intermediates for antitumor agents

INVENTOR(S): Ikeda, Shunichi; Kasai, Masaji; Saito, Hiromitsu

PATENT ASSIGNEE(S): Kyōwa Hakko Kogyo Kk, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 15 PP.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07048355	A	19950221	JP 1993-192105	19930803
PRIORITY APPLN. INFO.:			JP 1993-192105	19930803
OTHER SOURCE(S):	MARPAT	123:256702		
GI				



AB The title compds. I [R1, R2 = alkyl; X = H, halo; Y1 = H; Y2 = O, etc.; or Y1Y2 = N; Z = H, halo, etc.] are claimed. Pyrazoloacridinone II was prepared in a multiple step process from 4-acetyl-1-bromo-5,8-dimethoxy-9(10H)-acridone.


IT 142853-41-6P 142853-45-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of acridone and pyrazoloacridinone derivs. as intermediates for antitumor agents)


RN 142853-41-6 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-2-[[2-aminoethyl)amino]methyl]-7,10-dihydroxy- (9CI) (CA INDEX NAME)



RN 142853-45-0 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[2-(2-hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:490167 CAPLUS

DOCUMENT NUMBER: 117:90167


TITLE: Pyrazoloacridone derivatives and pharmaceuticals with antitumor activity containing them

INVENTOR(S): Mimura, Yukiteru; Shida, Yasushi; Kasai, Masaji;

10/551,816

PATENT ASSIGNEE(S): Ashizawa, Tadashi; Gomi, Katsushige
Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl.; 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 487097	A1	19920527	EP 1991-119896	19911121
EP 487097	B1	19981014		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05001064	A	19930108	JP 1991-301727	19911118
JP 06076409	B	19940928		
US 5220026	A	19930615	US 1991-793522	19911118
AT 172200	T	19981015	AT 1991-119896	19911121
ES 2125859	T3	19990316	ES 1991-119896	19911121
PRIORITY APPLN. INFO.:			JP 1990-320438	A 19901122
OTHER SOURCE(S):	CASREACT 117:90167; MARPAT 117:90167			
GI				



I

AB Certain pyrazoloacridone derivs. and pharmaceuticals with antitumor activity containing same are claimed. Treatment of 2-(bromomethyl)-5,8-dibromo-7,10-dimethoxypyrazolo[4,5,1-d,e]acridin-6-one with ethylenediamine followed by debromination and treatment with HBr to give 5-[(2-aminoethyl)amino]-2-[[aminoethyl)amino]methyl]-7,10-dihydroxypyrazolo[4,5,1-d,e]acridin-6-one (I). I was active against P388 ascites tumor in mice.


IT 142853-41-6P 142853-42-7P 142853-43-8P
142853-44-9P 142853-45-0P 142853-46-1P
142853-47-2P 142853-48-3P 142853-49-4P
142853-50-7P 142853-51-8P 142853-52-9P
142853-53-0P 142853-54-1P 142853-57-4P
142853-61-0P 142853-64-3P 142853-67-6P
142853-70-1P 142853-73-4P 142853-76-7P
142853-79-0P 142853-83-6P 142853-87-0P
142853-89-2P 142853-92-7P 142853-95-0P
142853-98-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as neoplasm inhibitor)


RN 142853-41-6 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-2-[[aminoethyl)amino]methyl]-7,10-dihydroxy- (9CI) (CA INDEX NAME)


10/551,816




RN 142853-42-7 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-2-[(diethylamino)methyl]-7,10-dihydroxy- (9CI) (CA INDEX NAME)



RN 142853-43-8 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 2-[(diethylamino)methyl]-5-[[2-(dimethylamino)ethyl]amino]-7,10-dihydroxy- (9CI) (CA INDEX NAME)




RN 142853-44-9 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-7,10-dihydroxy-2-[[2-(hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)



10/551,816


RN 142853-45-0 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[2-(2-hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 142853-46-1 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-2-[[2-(2-hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 142853-47-2 CAPLUS


CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-2-[[2-(2-hydroxyethyl)amino]methyl]-5-[[2-(methylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 142853-48-3 CAPLUS


CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[[2-(dimethylamino)ethyl]amino]-7,10-dihydroxy-2-[[2-(2-hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)

10/551,816




RN 142853-49-4 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 2-[[bis(2-hydroxyethyl)amino]ethyl]-5-[[2-(dimethylamino)ethyl]amino]-7,10-dihydroxy- (9CI) (CA INDEX NAME)



RN 142853-50-7 CAPLUS


CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-7,10-dihydroxy-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 142853-51-8 CAPLUS


CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-7,10-dihydroxy-2-[[[2-methoxyethyl]amino]methyl]- (9CI) (CA INDEX NAME)

10/551,816




RN 142853-52-9 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 142853-53-0 CAPLUS


CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 142853-54-1 CAPLUS


CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]-5-[[2-(4-morpholinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

10/551,816



RN 142853-57-4 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-2-[[2-aminoethyl]amino]methyl]-7,10-dihydroxy-, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 142853-61-0 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-2-[[diethylamino]methyl]-7,10-dihydroxy-, monohydrobromide (9CI) (CA INDEX NAME)


10/551,816



● HBr

RN 142853-64-3 CAPLUS


CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 2-[(diethylamino)methyl]-5-[[2-(dimethylamino)ethyl]amino]-7,10-dihydroxy-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 142853-67-6 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-7,10-dihydroxy-2-[[2-(hydroxyethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 142853-70-1 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-

10/551,816


dihydroxy-2-[[[(2-hydroxyethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-73-4 CAPLUS


CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-2-[[[(2-hydroxyethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-76-7 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-2-[[[(2-hydroxyethyl)amino]methyl]-5-[[2-(methylamino)ethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/551,816

RN 142853-79-0 CAPLUS


CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[[2-(dimethylamino)ethyl]amino]-7,10-dihydroxy-2-[[2-(2-hydroxyethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-83-6 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 2-[[bis(2-hydroxyethyl)amino]methyl]-5-[[2-(dimethylamino)ethyl]amino]-7,10-dihydroxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 142853-87-0 CAPLUS


CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-7,10-dihydroxy-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/551,816



● HCl


RN 142853-89-2 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-7,10-dihydroxy-2-[[2-(2-methoxyethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 142853-92-7 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/551,816



● HCl


RN 142853-95-0 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-98-3 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]-5-[[2-(4-morpholinyl)ethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

10/551,816



● HCl

=> d his

(FILE 'HOME' ENTERED AT 10:33:53 ON 11 JAN 2007)

FILE 'REGISTRY' ENTERED AT 10:34:07 ON 11 JAN 2007

L1 STRUCTURE UPLOADED

L2 4 S L1

L3 33 S L1 FULL


FILE 'CAPLUS' ENTERED AT 10:34:39 ON 11 JAN 2007

L4 5 S L3/PREP

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>